Esbriet Tablet, Coated
Product Images NDC 50242-122

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Esbriet (NDC 50242-122). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Genentech, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Esbriet 01)

Chemical structure diagram of the active ingredient in ESBRIET, showing the molecular arrangement with a phenyl ring connected to a nitrogen atom, which is linked to a methylated quinolinone ring.*

FDA Label Image

Figure 1 (Esbriet 02)

A cumulative distribution graph showing the percentage of patients versus absolute change in % predicted Forced Vital Capacity (FVC) from baseline to week 52. It compares ESBRIET (n=278) with placebo (n=277) across worsening (decrease in %FVC) and no decline (increase in %FVC) ranges, illustrating patient respiratory function outcomes.*

FDA Label Image

Figure 2 (Esbriet 03)

A line graph showing mean change in forced vital capacity (FVC) in mL over 52 weeks. Two groups compared: ESBRIET with 278 subjects (solid line) and placebo with 277 subjects (dashed line). Both lines show decreasing FVC over time, with ESBRIET group having less decline compared to placebo.*

FDA Label Image

Figure 3 (Esbriet 04)

A survival curve graph showing the percentage of patients alive over time in weeks, comparing ESBRIET (pirfenidone) and placebo groups. The graph plots survival rates for 623 ESBRIET patients and 624 placebo patients up to approximately 120 weeks, with a hazard ratio (HR) and 95% confidence interval displayed. Patient risk numbers at various time points are shown below the graph.*

FDA Label Image

Principal Display Panel (267 mg Bottle Carton)

Esbriet (pirfenidone) capsules 267 mg label showing the product name, active ingredient, dosage strength, and capsule count of 270. The label includes a caution to keep out of reach of children and displays the Genentech, Inc. logo as the labeler.*

FDA Label Image

Principal Display Panel (267 mg Tablet Bottle Carton)

Esbriet (pirfenidone) tablets 267 mg prescription medication label showing product name, strength, quantity of 270 tablets, and Genentech, Inc. as labeler. NDC 50242-122-06 visible with a safety warning to keep out of reach of children.*

FDA Label Image

Principal Display Panel (801 mg Tablet Bottle Carton)

Label for Esbriet 801 mg tablets (pirfenidone) by Genentech, Inc. The label shows the NDC number 50242-123-01, a warning to keep out of reach of children, and indicates 90 tablets in the package. It is marked Rx only.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.